/PRNewswire/ Supira Medical, Inc., a Shifamed portfolio company, announced today that its next generation percutaneous ventricular assist device (pVAD) was.
Supira's technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic
Results of the IMPLEMENT-HF Trial show that a virtual care team-guided strategy for guideline-directed medical therapy (GDMT) optimization was found to be safe and improve therapy among patients hospitalized with heart failure with reduced ejection fraction (HFrEF). Findings were presented during a Featured Clinical Research session on the final day of the American College of Cardiology Annual Scientific Session Together with the World Congress of Cardiology, being held March 4-6 in New Orleans, LA.